Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes : evidence from the Association of British Clinical Diabetologists (ABCD) study
Liarakos, Alexandros L Hasan, Nebras Crabtree, Thomas S J Leelarathna, Lalantha Hammond, Peter Hussain, Sufyan Haq, Masud Aslam, Aisha Gatdula, Erneda Gibb, Fraser W
Liarakos, Alexandros L
Hasan, Nebras
Crabtree, Thomas S J
Leelarathna, Lalantha
Hammond, Peter
Hussain, Sufyan
Haq, Masud
Aslam, Aisha
Gatdula, Erneda
Gibb, Fraser W
Citations
Altmetric:
Affiliation
University Hospitals of Derby and Burton NHS Foundation Trust; Manchester University NHS Foundation Trust; Harrogate and District NHS Trust; Sandwell and West Birmingham NHS Trust; et al.
Other Contributors
Publication date
2024-02-27
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Aims: To evaluate real-world outcomes in people with Type 1 Diabetes (PwT1D) initiated on Omnipod DASH® Insulin Management System. Methods: Anonymized clinical data were submitted to a secure web-based tool within the National Health Service network. Hemoglobin A1c (HbA1c), sensor-derived glucometrics, total daily dose of insulin (TDD), and patient-reported outcome changes between baseline and follow-up were assessed. Individuals were classified to "new-to-pump" (switched from multiple daily injections) and "established-on-pump" (switched from a tethered insulin pump) groups. Results: 276 individuals from 11 centers [66.7 % female; 92 % White British; median age 41 years (IQR 20-50); diabetes duration 20 years (IQR 11-31); 49.3 % within "new-to-pump" group] were included. Baseline HbA1c was 8.0 ± 1.3 % (64 ± 14 mmol/mol). At follow-up [3 years (IQR 1.5-3.2)], HbA1c reduced by 0.3 % [(3 mmol/mol); p = 0.002] across the total population, 0.4 % [(5 mmol/mol); p = 0.001] in those "new-to-pump" and remained unchanged in those "established-on-pump". TDD decreased in the "new-to-pump" cohort (baseline:44.9 ± 21.0units vs follow-up:38.1 ± 15.4units, p = 0.002). Of those asked, 141/143 (98.6 %) stated Omnipod DASH had a positive impact on quality of life. Conclusions: Omnipod DASH was associated with improvements in HbA1c in PwT1D "new-to-pump" and maintained previous HbA1c levels in those "established-on-pump". User satisfaction in all groups and TDD reduction in those "new-to-pump" were reported.
Citation
Liarakos AL, Hasan N, Crabtree TSJ, Leelarathna L, Hammond P, Hussain S, Haq M, Aslam A, Gatdula E, Gibb FW, Lumb A, Bull K, Chinnasamy E, Carrieri G, Williams DM, Choudhary P, Ryder REJ, Wilmot EG. Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study. Diabetes Res Clin Pract. 2024 Mar;209:111597. doi: 10.1016/j.diabres.2024.11159
Type
Article